Literature DB >> 12356187

Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.

T A Ikizler1, J D Morrow, L J Roberts, J A Evanson, B Becker, R M Hakim, Y Shyr, J Himmelfarb.   

Abstract

AIMS: Cardiovascular mortality has been reported to be 10- to 20-fold higher in chronic dialysis patients than in the age-matched general population. It has been suggested that increased oxidant stress and resulting vascular wall injury due to uremia and the hemodialysis procedure may be one of the mechanisms predisposing to these cardiovascular complications. Further, hemodialysis membrane bioincompatibility can contribute to increased oxidative stress and prevalence of inflammation. MATERIALS: We studied 18 chronic hemodialysis (CHD) patients (age 62.8 +/- 14.7 years, 39% male, 61% African-American, 44% insulin-dependent diabetic, 61% smokers, 61% with documented coronary artery disease) during hemodialysis with 2 membranes with different flux and complement activating properties.
METHODS: We have measured free and phospholipid-bound F2-isoprostane (F2-IsoP) levels, a sensitive marker of oxidative stress, in CHD patients and compared them to levels in healthy subjects. We have also examined the acute effects of the hemodialysis procedure using both biocompatible and bioincompatible membranes on F2-IsoP levels.
RESULTS: The results indicated that, compared to controls, both free (96.2 +/- 48.8 pg/ml versus 37.6 +/- 17.2 pg/ml) and bound F2-IsoP (220.4 +/- 154.8 pg/ml versus 146.8 +/- 58.4 pg/ml) levels were significantly higher (p < 0.05 for both). There was a statistically significant decrease in free F2-IsoP concentrations at 15 and 30 minutes of HD, which rebounded to baseline levels at the completion of the procedure. There were no significant differences in F2-IsoP concentrations between the 2 study dialyzers at any time point. Age, smoking status, diabetes mellitus and presence of cardiovascular disease were also not correlated with F2-IsoP levels in this patient population. There was a significant association between predialysis F2-IsoP and C-reactive protein concentrations.
CONCLUSION: Using a sensitive and specific assay for the measurement of F2-IsoP, we demonstrated that CHD patients are under increased oxidative stress. During a single hemodialysis treatment, the hemodialysis membrane appears to have no discernable effect on oxidative stress status. Measurement of F2-isoprostanes may be a useful biomarker of oxidative stress status as well as in developing new therapeutic strategies to ameliorate inflammatory and oxidative injury in this patient population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356187     DOI: 10.5414/cnp58190

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  37 in total

1.  Relation of blood cadmium, lead, and mercury levels to biomarkers of lipid peroxidation in premenopausal women.

Authors:  Anna Z Pollack; Enrique F Schisterman; Lynn R Goldman; Sunni L Mumford; Neil J Perkins; Michael S Bloom; Carole B Rudra; Richard W Browne; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2012-02-02       Impact factor: 4.897

2.  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease.

Authors:  Luis F Ramos; Jane Kane; Ellen McMonagle; Phuong Le; Pingsheng Wu; Ayumi Shintani; Talat Alp Ikizler; Jonathan Himmelfarb
Journal:  J Ren Nutr       Date:  2010-12-24       Impact factor: 3.655

3.  Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Authors:  Leigh Anne Redhage; Ayumi Shintani; David W Haas; Nkiruka Emeagwali; Milica Markovic; Ikwo Oboho; Christopher Mwenya; Husamettin Erdem; Edward P Acosta; Jason D Morrow; Todd Hulgan
Journal:  HIV Clin Trials       Date:  2009 May-Jun

4.  Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.

Authors:  Matthew B Rivara; Catherine K Yeung; Cassianne Robinson-Cohen; Brian R Phillips; John Ruzinski; Denise Rock; Lori Linke; Danny D Shen; T Alp Ikizler; Jonathan Himmelfarb
Journal:  Am J Kidney Dis       Date:  2016-12-04       Impact factor: 8.860

5.  The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients.

Authors:  I Giannikouris
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

6.  Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue.

Authors:  Chun Hu; Ming Yang; Xuejing Zhu; Peng Gao; Shikun Yang; Yachun Han; Xianghui Chen; Li Xiao; Shuguang Yuan; Fuyou Liu; Yashpal S Kanwar; Lin Sun
Journal:  Ther Apher Dial       Date:  2017-12-22       Impact factor: 1.762

7.  Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation.

Authors:  So Yeon J Kong; Roberd M Bostick; W Dana Flanders; William M McClellan; Bharat Thyagarajan; Myron D Gross; Suzanne Judd; Michael Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-17       Impact factor: 4.254

8.  Glycemic load is associated with oxidative stress among prevalent maintenance hemodialysis patients.

Authors:  Chutatip Limkunakul; Mary B Sundell; Brianna Pouliot; Amy J Graves; Ayumi Shintani; Talat A Ikizler
Journal:  Nephrol Dial Transplant       Date:  2013-12-17       Impact factor: 5.992

9.  Inflammation, kidney function and albuminuria in the Framingham Offspring cohort.

Authors:  Ashish Upadhyay; Martin G Larson; Chao-Yu Guo; Ramachandran S Vasan; Izabella Lipinska; Christopher J O'Donnell; Sekar Kathiresan; James B Meigs; John F Keaney; Jian Rong; Emelia J Benjamin; Caroline S Fox
Journal:  Nephrol Dial Transplant       Date:  2010-08-03       Impact factor: 5.992

10.  Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients.

Authors:  Hong Xu; Makoto Watanabe; Abdul Rashid Qureshi; Olof Heimbürger; Peter Bárány; Björn Anderstam; Monica Eriksson; Peter Stenvinkel; Bengt Lindholm
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.